NCT00963417View on ClinicalTrials.gov

Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02

NACompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

August 3, 2009

Primary Completion Date

March 11, 2011

Study Completion Date

October 23, 2024

Conditions
Breast CancerOsteoporosis
Interventions
OTHER

laboratory biomarker analysis

Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.

PROCEDURE

dual x-ray absorptiometry

Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).

Trial Locations (13)

Unknown

Royal Brisbane and Women's Hospital, Brisbane

Peter MacCallum Cancer Center, East Melbourne

Box Hill Hospital, Melbourne

Maroondah Hospital, Melbourne

Royal Perth Hospital, Perth

Centre Hospitalier Regional de Huy, Huy

UZ Leuven, Leuven

C.H.U. Sart Tilman, Liège

CHR Citadelle, Liège

C.H.P.L.T. de Verviers, Verviers

Inselspital Bern, Bern

Kantonsspital St.Gallen, Sankt Gallen

CH-6500

Oncology Institute of Southern Switzerland, Bellinzona

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Breast International Group

OTHER

lead

ETOP IBCSG Partners Foundation

NETWORK

NCT00963417 - Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02 | Biotech Hunter | Biotech Hunter